id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2024-E-3572-0007,FDA,FDA-2024-E-3572,Determination of Regulatory Review Period for Purposes of Patent Extension; TEVIMBRA,Notice,Determinations,2026-02-26T05:00:00Z,2026,2,2026-02-26T05:00:00Z,2026-04-28T03:59:59Z,2026-02-26T20:52:55Z,2026-03851,1,0,09000064b91deb48
FDA-2024-E-3572-0006,FDA,FDA-2024-E-3572,Letter to U. S. Patent and Trademark Office,Other,Letter(s),2025-12-03T05:00:00Z,2025,12,2025-12-03T05:00:00Z,,2025-12-03T20:15:25Z,,0,0,09000064b90aa4d3
FDA-2024-E-3572-0005,FDA,FDA-2024-E-3572,Letter from U. S. Patent and Trademark Office,Other,Letter(s),2025-10-20T04:00:00Z,2025,10,2025-10-20T04:00:00Z,,2025-10-20T20:10:05Z,,0,0,09000064b9035b6b
FDA-2024-E-3572-0004,FDA,FDA-2024-E-3572,Letter to U.S. Patent and Trademark Office,Other,Letter(s),2025-08-27T04:00:00Z,2025,8,2025-08-27T04:00:00Z,,2025-08-27T22:25:18Z,,0,0,09000064b8f1ee42
FDA-2024-E-3572-0001,FDA,FDA-2024-E-3572,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2024-08-09T04:00:00Z,2024,8,2024-08-09T04:00:00Z,,2024-08-09T18:19:54Z,,0,0,090000648660e09d
FDA-2024-E-3572-0003,FDA,FDA-2024-E-3572,Requirement for Information,Other,Letter(s),2024-08-09T04:00:00Z,2024,8,2024-08-09T04:00:00Z,,2024-08-09T18:21:37Z,,0,0,090000648660e09f
FDA-2024-E-3572-0002,FDA,FDA-2024-E-3572,Patent Extension Application from Foley & Lardner LLP (on behalf of BeiGene Switzerland GmbH),Other,Application,2024-08-09T04:00:00Z,2024,8,2024-08-09T04:00:00Z,,2024-08-09T18:21:32Z,,0,0,090000648660e09e